CPIX vs. ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, RPRX, and CORT
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.
Cumberland Pharmaceuticals vs. Its Competitors
Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Comparatively, 44.9% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Assembly Biosciences has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500.
In the previous week, Assembly Biosciences had 2 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 11 mentions for Assembly Biosciences and 9 mentions for Cumberland Pharmaceuticals. Assembly Biosciences' average media sentiment score of 0.72 beat Cumberland Pharmaceuticals' score of 0.48 indicating that Assembly Biosciences is being referred to more favorably in the media.
Assembly Biosciences currently has a consensus target price of $33.00, suggesting a potential upside of 37.67%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Assembly Biosciences is more favorable than Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Cumberland Pharmaceuticals has a net margin of -6.97% compared to Assembly Biosciences' net margin of -117.20%. Cumberland Pharmaceuticals' return on equity of 7.68% beat Assembly Biosciences' return on equity.
Summary
Assembly Biosciences beats Cumberland Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPIX) was last updated on 8/11/2025 by MarketBeat.com Staff
MarketBeat All Access Sale